Prime Medicine Secures $191.4M Cash Runway, Targets Wilson Disease IND in H1 2026
Prime Medicine ended 2025 with $191.4M in cash, funding operations into 2027, while net loss was $201.1M and R&D expenses held at $160.6M as it deprioritized its CGD program. The company plans IND/CTA submissions for Wilson Disease in H1 2026 and Alpha-1 Antitrypsin Deficiency mid-2026, with clinical data expected in 2027.
1. Financial Results and Cash Position
Prime Medicine closed 2025 with $191.4 million in cash, cash equivalents and investments and reported a net loss of $201.1 million. Research and development expenses remained steady at $160.6 million as the company optimized its workforce and reprioritized assets.
2. Pipeline Focus Shift
The company has deprioritized its Chronic Granulomatous Disease program to concentrate on its in vivo liver franchise targeting Wilson Disease and Alpha-1 Antitrypsin Deficiency. This strategic shift aims to streamline resources toward high-priority clinical milestones.
3. Upcoming Clinical Milestones
Prime Medicine plans to submit an IND or CTA for its Wilson Disease program in H1 2026 followed by a mid-2026 submission for its AATD program. Initial clinical data for both indications are anticipated in 2027.
4. Collaborations and Other Programs
In addition to its liver-focused programs, Prime Medicine continues advancing its Cystic Fibrosis program with foundation support and maintains a CAR-T collaboration with Bristol Myers Squibb.